Comprehensive analysis of EGFR mutations in cfDNA and CTCs could be more informative regarding the treatment monitoring of NSCLC patients as it was recently demonstrated in studies that included both liquid biopsy biomarkers [60,61]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.